Q-omics provides the consensus-scored RPL17P36 profile across patient tissues and cancer cell-line models. RPL17P36 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL17P36 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL17P36 RNA expression shows 16,920 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where RPL17P36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P36 survival associations across molecular data types. RPL17P36 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P36 RNA expression–survival associations across cancer types. High RPL17P36 expression shows unfavorable associations in ACC, LIHC, SARC and UCEC, but favorable associations in CESC and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL17P36 RNA expression.
This table summarizes RPL17P36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P36 shows lower tumor expression in BRCA, PAAD and UCEC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RPL17P36 RNA expression in tumor versus normal tissue (log2 FC = +0.662, t-test p < 0.001).
This table shows molecular features associated with RPL17P36 in patient tissues and cancer cell lines. In patient samples, RPL17P36 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
